5 Conclusions
We demonstrated that empagliflozin inhibited chondrocytes ECM
degradation, inflammation and cellular senescence in vitro and prevented
cartilage degeneration in vivo by suppressing the NF-κB pathway
activation. Our findings indicate a therapeutic potential of
empagliflozin in OA treatment.